Informações:
Falhas:
ID
41201
Descrição
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01263704
Link
https://clinicaltrials.gov/show/NCT01263704
Palavras-chave
Versões (1)
- 12/07/2020 12/07/2020 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
12 de julho de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Lymphocytic Leukemia, Chronic NCT01263704
Eligibility Lymphocytic Leukemia, Chronic NCT01263704
- StudyEvent: Eligibility
Similar models
Eligibility Lymphocytic Leukemia, Chronic NCT01263704
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adult | Age
Item
adult patients, >/= 65 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
B-cell chronic lymphocytic leukemia Untreated
Item
previously untreated b-cell chronic lymphocytic leukemia (cll)
boolean
C0475774 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,2])
Binet Staging System
Item
binet stage c or active binet stage a and b disease
boolean
C1511118 (UMLS CUI [1])
Prior Therapy Chronic Lymphocytic Leukemia
Item
prior treatment for cll
boolean
C1514463 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C0023434 (UMLS CUI [1,2])
Chronic Lymphocytic Leukemia | Richter's syndrome
Item
cll with transformation (richter's syndrome)
boolean
C0023434 (UMLS CUI [1])
C0349631 (UMLS CUI [2])
C0349631 (UMLS CUI [2])
Central Nervous System Involvement Chronic Lymphocytic Leukemia Suspected | Central Nervous System Involvement Chronic Lymphocytic Leukemia
Item
suspected or known cns involvement of cll
boolean
C4050309 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C0750491 (UMLS CUI [1,3])
C4050309 (UMLS CUI [2,1])
C0023434 (UMLS CUI [2,2])
C0023434 (UMLS CUI [1,2])
C0750491 (UMLS CUI [1,3])
C4050309 (UMLS CUI [2,1])
C0023434 (UMLS CUI [2,2])
Renal Insufficiency | Liver Dysfunction
Item
impaired renal or hepatic function
boolean
C1565489 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
C0086565 (UMLS CUI [2])
HIV Seropositivity | Hepatitis B | Hepatitis C | Hepatitis B surface antigen positive | Communicable Disease | Communicable Disease Uncontrolled
Item
hiv positivity, active hepatitis b/c or hbv surface antigen positive, or any active or uncontrolled infections
boolean
C0019699 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
C0149709 (UMLS CUI [4])
C0009450 (UMLS CUI [5])
C0009450 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
C0149709 (UMLS CUI [4])
C0009450 (UMLS CUI [5])
C0009450 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Antibody to hepatitis B core antigen | Hepatitis B In the past | Hepatitis B surface antigen negative | Hepatitis B surface antibody positive | Hepatitis B surface antigen negative | Hepatitis B DNA Positive Polymerase Chain Reaction
Item
patients with anti-hbv core antibodies (past infection with hbv) but who are negative for hbvsag (either anti-hbs ab positive or negative) and are positive for hbv-dna by pcr analysis
boolean
C0312631 (UMLS CUI [1])
C0019163 (UMLS CUI [2,1])
C1444637 (UMLS CUI [2,2])
C0919711 (UMLS CUI [3])
C0149708 (UMLS CUI [4])
C0919711 (UMLS CUI [5])
C5206277 (UMLS CUI [6,1])
C0032520 (UMLS CUI [6,2])
C0019163 (UMLS CUI [2,1])
C1444637 (UMLS CUI [2,2])
C0919711 (UMLS CUI [3])
C0149708 (UMLS CUI [4])
C0919711 (UMLS CUI [5])
C5206277 (UMLS CUI [6,1])
C0032520 (UMLS CUI [6,2])
Comorbidity Requirement Steroid therapy chronic
Item
concomitant diseases requiring chronic steroid administration
boolean
C0009488 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0149783 (UMLS CUI [1,3])
C0205191 (UMLS CUI [1,4])
C1514873 (UMLS CUI [1,2])
C0149783 (UMLS CUI [1,3])
C0205191 (UMLS CUI [1,4])
Second Primary Cancer | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of female breast | Exception Carcinoma in situ of prostate
Item
active second malignancy within the 2 years prior to study (except for non-melanoma skin cancer and in situ cervix or breast or prostate carcinoma)
boolean
C0751623 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0686288 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0154088 (UMLS CUI [5,2])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0686288 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0154088 (UMLS CUI [5,2])
ECOG performance status
Item
ecog performance status >/= 3
boolean
C1520224 (UMLS CUI [1])